Performance Characteristics of the Cepheid Xpert MTB/RIF Test in a Tuberculosis Prevalence Survey

被引:48
作者
Dorman, Susan E. [1 ]
Chihota, Violet N. [2 ]
Lewis, James J. [2 ,3 ]
Shah, Maunank [1 ]
Clark, David [2 ]
Grant, Alison D. [3 ]
Churchyard, Gavin J. [2 ,3 ,4 ]
Fielding, Katherine L. [3 ]
机构
[1] Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA
[2] Aurum Inst Hlth Res, Johannesburg, South Africa
[3] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England
[4] Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South Africa
来源
PLOS ONE | 2012年 / 7卷 / 08期
基金
美国国家卫生研究院;
关键词
MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; RIFAMPIN RESISTANCE; RANDOMIZED-TRIAL; DIAGNOSIS; HIV; ASSAY; ERA;
D O I
10.1371/journal.pone.0043307
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Xpert MTB/RIF ("Xpert'') is a molecular test for detection of Mycobacterium tuberculosis (MTB) in sputum. Performance characteristics have been established for its use during passive tuberculosis (TB) case detection in symptomatic TB suspects, but Xpert performance has not been assessed in other settings. Objectives were to determine Xpert performance and costs in the context of a TB prevalence survey. Methodology/Principal Findings: This was a diagnostic sub-study of a TB prevalence survey conducted in gold mining companies in South Africa. Sputa (one per participant) were tested using smear microscopy, liquid culture (reference comparator), and Xpert. Costs were collected using an ingredients approach and analyzed using a public health program perspective. 6893 participants provided a sputum specimen. 187/6893 (2.7%) were positive for MTB in culture, 144/6893 (2.1%) were positive for MTB by Xpert, and 91/6893 (1.3%) were positive for acid fast bacilli by microsocopy. Sensitivity, specificity, positive predictive value, and negative predictive value for detection of MTB by Xpert were 62.6% (95% confidence interval [CI] 55.2, 69.5), 99.6% (99.4, 99.7), 81.3% (73.9, 87.3), and 98.9 (98.6, 98.8); agreement between Xpert and culture was 98.5% (98.2, 98.8). Sensitivity of microscopy was 17.6% (12.5, 23.9). When individuals with a history of TB treatment were excluded from the analysis, Xpert specificity was 99.8 (99.7, 99.9) and PPV was 90.6 (83.3, 95.4) for detection of MTB. For the testing scenario of 7000 specimens with 2.7% of specimens culture positive for MTB, costs were $165,690 for Xpert and $115,360 for the package of microscopy plus culture. Conclusion: In the context of a TB prevalence survey, the Xpert diagnostic yield was substantially higher than that of microscopy yet lower than that of liquid culture. Xpert may be useful as a sole test for TB case detection in prevalence surveys, particularly in settings lacking capacity for liquid culture.
引用
收藏
页数:8
相关论文
共 25 条
  • [1] Prevalence of Tuberculosis, HIV and Respiratory Symptoms in Two Zambian Communities: Implications for Tuberculosis Control in the Era of HIV
    Ayles, Helen
    Schaap, Albertus
    Nota, Amos
    Sismanidis, Charalambos
    Tembwe, Ruth
    De Haas, Petra
    Muyoyeta, Monde
    Beyers, Nulda
    Godfrey-Faussett, Peter
    [J]. PLOS ONE, 2009, 4 (05):
  • [2] ZAMSTAR, The Zambia South Africa TB and HIV Reduction study: Design of a 2 x 2 factorial community randomized trial
    Ayles, Helen M.
    Sismanidis, Charalambos
    Beyers, Nulda
    Hayes, Richard J.
    Godfrey-Faussett, Peter
    [J]. TRIALS, 2008, 9 (1)
  • [3] Containment of Bioaerosol Infection Risk by the Xpert MTB/RIF Assay and Its Applicability to Point-of-Care Settings
    Banada, Padmapriya P.
    Sivasubramani, Satheesh K.
    Blakemore, Robert
    Boehme, Catharina
    Perkins, Mark D.
    Fennelly, Kevin
    Alland, David
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2010, 48 (10) : 3551 - 3557
  • [4] Evaluation of the Analytical Performance of the Xpert MTB/RIF Assay
    Blakemore, Robert
    Story, Elizabeth
    Helb, Danica
    Kop, JoAnn
    Banada, Padmapriya
    Owens, Michelle R.
    Chakravorty, Soumitesh
    Jones, Martin
    Alland, David
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2010, 48 (07) : 2495 - 2501
  • [5] Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study
    Boehme, Catharina C.
    Nicol, Mark P.
    Nabeta, Pamela
    Michael, Joy S.
    Gotuzzo, Eduardo
    Tahirli, Rasim
    Gler, Ma Tarcela
    Blakemore, Robert
    Worodria, William
    Gray, Christen
    Huang, Laurence
    Caceres, Tatiana
    Mehdiyev, Rafail
    Raymond, Lawrence
    Whitelaw, Andrew
    Sagadevan, Kalaiselvan
    Alexander, Heather
    Albert, Heidi
    Cobelens, Frank
    Cox, Helen
    Alland, David
    Perkins, Mark D.
    [J]. LANCET, 2011, 377 (9776) : 1495 - 1505
  • [6] Rapid Molecular Detection of Tuberculosis and Rifampin Resistance
    Boehme, Catharina C.
    Nabeta, Pamela
    Hillemann, Doris
    Nicol, Mark P.
    Shenai, Shubhada
    Krapp, Fiorella
    Allen, Jenny
    Tahirli, Rasim
    Blakemore, Robert
    Rustomjee, Roxana
    Milovic, Ana
    Jones, Martin
    O'Brien, Sean M.
    Persing, David H.
    Ruesch-Gerdes, Sabine
    Gotuzzo, Eduardo
    Rodrigues, Camilla
    Alland, David
    Perkins, Mark D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (11) : 1005 - 1015
  • [7] Review of false-positive cultures for Mycobacterium tuberculosis and recommendations for avoiding unnecessary treatment
    Burman, WJ
    Reves, RR
    [J]. CLINICAL INFECTIOUS DISEASES, 2000, 31 (06) : 1390 - 1395
  • [8] Comparison of two active case-finding strategies for community-based diagnosis of symptomatic smear-positive tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): a cluster-randomised trial
    Corbett, Elizabeth L.
    Bandason, Tsitsi
    Duong, Trinh
    Dauya, Ethel
    Makamure, Beauty
    Churchyard, Gavin J.
    Williams, Brian G.
    Munyati, Shungu S.
    Butterworth, Anthony E.
    Mason, Peter R.
    Mungofa, Stanley
    Hayes, Richard J.
    [J]. LANCET, 2010, 376 (9748) : 1244 - 1253
  • [9] Measuring tuberculosis burden, trends, and the impact of control programmes
    Dye, C.
    Bassili, A.
    Bierrenbach, A. L.
    Broekmans, J. F.
    Chadha, V. K.
    Glaziou, P.
    Gopi, P. G.
    Hosseini, M.
    Kim, S. J.
    Manissero, D.
    Onozaki, I.
    Rieder, H. L.
    Scheele, S.
    van Leth, F.
    van der Werf, M.
    Williams, B. G.
    [J]. LANCET INFECTIOUS DISEASES, 2008, 8 (04) : 233 - 243
  • [10] Thibela TB: Design and methods of a cluster randomised trial of the effect of community-wide isoniazid preventive therapy on tuberculosis amongst gold miners in South Africa
    Fielding, Katherine L.
    Grant, Alison D.
    Hayes, Richard J.
    Chaisson, Richard E.
    Corbett, Elizabeth L.
    Churchyard, Gavin J.
    [J]. CONTEMPORARY CLINICAL TRIALS, 2011, 32 (03) : 382 - 392